EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 161 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,480,580 | +0.1% | 347,532 | +23.3% | 0.00% | 0.0% |
| Q2 2023 | $5,477,123 | +64802.5% | 281,745 | -5.3% | 0.00% | -40.0% |
| Q1 2023 | $8,439 | +222.6% | 297,466 | +232.4% | 0.01% | +400.0% |
| Q4 2022 | $2,616 | -99.9% | 89,503 | -45.6% | 0.00% | -66.7% |
| Q3 2022 | $4,350,000 | -68.9% | 164,643 | -47.7% | 0.00% | -66.7% |
| Q2 2022 | $13,984,000 | +2170.1% | 314,739 | +2428.4% | 0.01% | – |
| Q1 2022 | $616,000 | -5.8% | 12,448 | -3.1% | 0.00% | – |
| Q4 2021 | $654,000 | -14.7% | 12,851 | -6.5% | 0.00% | – |
| Q3 2021 | $767,000 | -73.2% | 13,748 | -79.5% | 0.00% | -100.0% |
| Q2 2021 | $2,864,000 | -20.7% | 66,907 | -22.7% | 0.00% | -33.3% |
| Q1 2021 | $3,611,000 | +23.9% | 86,505 | +38.2% | 0.00% | +50.0% |
| Q4 2020 | $2,915,000 | +156.8% | 62,596 | +134.4% | 0.00% | +100.0% |
| Q3 2020 | $1,135,000 | -78.9% | 26,710 | -76.2% | 0.00% | -85.7% |
| Q2 2020 | $5,386,000 | +1809.9% | 112,265 | +1731.1% | 0.01% | +600.0% |
| Q1 2020 | $282,000 | -82.8% | 6,131 | -78.9% | 0.00% | -66.7% |
| Q3 2019 | $1,641,000 | +169.9% | 29,021 | +165.8% | 0.00% | +200.0% |
| Q2 2019 | $608,000 | -93.8% | 10,919 | -94.3% | 0.00% | -93.3% |
| Q1 2019 | $9,742,000 | -15.1% | 192,948 | -32.2% | 0.02% | -16.7% |
| Q4 2018 | $11,473,000 | +1345.0% | 284,753 | +2385.0% | 0.02% | +1700.0% |
| Q3 2018 | $794,000 | -28.7% | 11,459 | -45.0% | 0.00% | -50.0% |
| Q4 2017 | $1,113,000 | -83.6% | 20,841 | -75.8% | 0.00% | -83.3% |
| Q2 2017 | $6,804,000 | +2190.9% | 86,245 | +2307.1% | 0.01% | +1100.0% |
| Q1 2017 | $297,000 | -95.0% | 3,583 | -95.2% | 0.00% | -91.7% |
| Q4 2016 | $5,969,000 | -17.5% | 75,232 | -59.7% | 0.01% | -29.4% |
| Q2 2016 | $7,235,000 | +127.6% | 186,512 | +137.6% | 0.02% | +112.5% |
| Q1 2016 | $3,179,000 | +547.5% | 78,503 | +1317.5% | 0.01% | +700.0% |
| Q4 2015 | $491,000 | -45.6% | 5,538 | -50.3% | 0.00% | -50.0% |
| Q2 2015 | $902,000 | -37.1% | 11,154 | -67.4% | 0.00% | -33.3% |
| Q1 2015 | $1,435,000 | +775.0% | 34,251 | +165.5% | 0.00% | – |
| Q1 2014 | $164,000 | – | 12,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |